Translate this page into:
Elizabethkingia meningoseptica bacteremia in immunocompromised hosts: The first case series from India
*Corresponding author: Dr. Vishal Jayakar. vishal.jayakar@kingstonhospital.nhs.uk
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Background: Although Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) infections in immunocompromised hosts have been recognised, clinical data detailing these infections remain limited, especially from India. Antimicrobial susceptibility data on E. meningoseptica remain very limited, with no established breakpoints by Clinical and Laboratory Standards Institute (CLSI). The organism is usually multidrug resistant to antibiotics usually prescribed for treating Gram-negative bacterial infections, a serious challenge to the patient and the treating clinicians. Materials and Methods: The analysis was done in a tertiary care oncology and stem cell transplant center. Susceptibility testing and identification of E. meningoseptica was done using Vitek auto analyzer. Records of immunocompromised patients with E. meningoseptica bacteremia were analysed from January 2009 to March 2012. Results: A total of 29 E. meningoseptica bacteremia cases were documented between 2009 and 2012. Eleven patients were immunocompromised. Three were post stem cell transplant and one was post cord blood transplant. The mean age of the patients was 48.4 years. Mean Charlson’s comorbidity index was 5.7. Four had solid organ malignancies, five had hematological malignancies, and two had lymphoreticular malignancy. Eight patients had received chemotherapy. Mean Apache II score was 18. Mean Pitts score for bacteremia was 4.7. Two were neutropenic (one post SCT, one MDS post chemo) with a mean white blood cell (WBC) count of 450/mm3. Ten had a line at the time of bacteremia. Mean duration of the line prior to bacteremia was 8 days. Eight had line-related bacteremia. Three had pneumonia with secondary bacteremia. All received combination therapy with two or more antibiotics which included cotrimoxazole, rifampicin, piperacillin–tazobactam, tigecycline, or cefepime–tazobactam. All the isolates showed in vitro resistance to ciprofloxacin. Five patients died, but a multivariate analysis was not done to calculate the attributable mortality. Conclusion: In our study, central line was the commonest risk factor for E. meningosepticum bacteremia, although a multivariate analysis was not done. There has not been much of a change in the susceptibility pattern of these organisms over 3 years, with good susceptibility to piperacillin–tazobactam and cotrimoxazole. Even though uncommon, E. meningoseptica is an important pathogen, especially in immunocompromised hosts with indwelling devices.
Keywords
References
- King EO. Studies on a group of previously unclassified bacteria associated with meningitis in infants. Am J Clin Pathol 1959;31:241-7.
- Ceyhan M, Celik M. Elizabethkingiameningosepticum (Chryseobacteriummeningosepticum) Infections in Children. Int J Pediatr 2011:215-37.
- Lin PY, Chu C, Su LH, Huang CT, Chang WY, Chiu CH. Microbiological Analysis of Bloodstream Infections Caused by Chryseobacteriummeningosepticum in Nonneonatal Patients. J Clin Microbiol 2004;42:3353-5.
- Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol 2004;42:445-8.
- Wayne PA. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Clinical and Laboratory Standards Institute 2009;29:M100-S19.
- Mouton JW, Melchers R, Mil AV. In Vitro Activity of Cefepime alone and in combination with Tazobactam against ESBL producers. Poster session presented at ICAAC. Boston, USA: 2010. p. A- 2251.
- Hsu MS, Liao CH, Huang YT, Liu CY, Yang CJ, Kao KL, et al. Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingiameningoseptica (Chryseobacteriummeningosepticum) bacteremia at a medical center in Taiwan, 1999-2006. Eur J Clin Microbiol Infect Dis 2011;30:1271-8.
- Du Moulin GC. Airway colonization by Flavobacterium in an intensive care unit. J Clin Microbiol 1979;10:155-60.
- Hoque SN, Graham J, Kaufmann ME, Tabaqchali S. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. J Hosp Infect 2001;47:188-92.
- Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: Report from the SENTRY antimicrobial surveillance program (1997-2001). J Clin Microbiol 2004;42:445-8.
- Bloch KC, Nadarajah R, Jacobs R. Chryseobacteriummeningosepticum: An emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Medicine (Baltimore) 1997;76:30-41.
- Arvanitidou M, Vayona A, Spanakis N, Tsakris A. Occurrence and antimicrobial resistance of Gram-negative bacteria isolated in haemodialysis water and dialysate of renal units: Results of a Greek multicentre study. J Appl Microbiol 2003;95:180-5.
- Lin YT, Chiu CH, Chan YJ, Lin ML, Yu KW, Wang FD, et al. Clinical and microbiological analysis of Elizabethkingiameningoseptica bacteremia in adult patients in Taiwan. Scand J Infect Dis 2009;41:628-34.
- Isaac MI, Neetoo Y. An outbreak of Elizabethkingiameningoseptica neonatal meningitis in Mauritius. J Infect Dev Ctries 2011;5:834-9.
- Hirsh BE, Wong B, Kiehn TE, Gee T, Armstrong D. Flavobacterium meningosepticum bacteremia in an adult with acute leukemia. Use of rifampin to clear persistent infection. Diagn Microbiol Infect Dis 1986;4:65-9.
- Di Pentima MC, Mason EO Jr, Kaplan SL. In Vitro antibiotic synergy against Flavobacterium meningosepticum: Implications for therapeutic options. Clin Infect Dis 1998;26:1169-76.
- Du Moulin GC. Airway colonization by Flavobacterium in an intensive care unit. J Clin Microbiol 1979;10:155-60.
- Fraser SL, Jorgensen JH. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob Agents Chemother 1997;41:2738-41.
- Lin PY, Chen HL, Huang CT, Su LH, Chiu CH. Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in Chryseobacteriummeningosepticum bacteremia. Int J Antimicrob Agents 2010;36:436-40.